140 related articles for article (PubMed ID: 28757336)
1. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
Van Der Steen N; Mentens Y; Ramael M; Leon LG; Germonpré P; Ferri J; Gandara DR; Giovannetti E; Peters GJ; Pauwels P; Rolfo C
Clin Lung Cancer; 2018 Jan; 19(1):35-41. PubMed ID: 28757336
[TBL] [Abstract][Full Text] [Related]
2. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
3. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
Lambros L; Guibourg B; Uguen A
Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
[No Abstract] [Full Text] [Related]
4. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
5. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
6. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
[TBL] [Abstract][Full Text] [Related]
7. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
[No Abstract] [Full Text] [Related]
9. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
12. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
13. [National variation in molecular diagnostics in metastatic lung cancer].
Kuijpers CCHJ; van den Heuvel MM; Overbeek LIH; van Slooten HJ; van Lindert ASR; Damhuis RAM; Willems SM
Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570921
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
15. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
16. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
18. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q; Gou Q; Gan X; Xie Y
Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
[TBL] [Abstract][Full Text] [Related]
20. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]